.

Medical professionals are cautiously optimistic about a new blood test that can screen for more than 50 types of cancers and costs less than $1,000.

The Galleri liquid biopsy looks for a shared cancer signal in DNA shed by tumors in the bloodstream. More than 130,000 of the prescription-only tests have been sold since they became available in June 2021, according to the test maker Grail. Despite its growing popularity, however, some cancer experts are encouraging caution.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Employee Participation
Employee-Paid
Employer-Paid